Healthcare products company West Pharmaceutical Services (NYSE:WST)
will be reporting results tomorrow before market open. Here’s what investors should know.
Diversified science and technology company Danaher (NYSE:DHR) announced better-than-expected revenue in Q1 CY2025, but sales were flat year on year at $5.74 billion. Guidance for next quarter’s revenue was better than expected at $5.92 billion at the midpoint, 1.4% above analysts’ estimates. Its non-GAAP profit of $1.88 per share was 14.4% above analysts’ consensus estimates.
Shares of diversified science and technology company Danaher (NYSE:DHR)
jumped 6.6% in the afternoon session after the company reported impressive first quarter 2025 results, which beat analysts' organic revenue and EPS expectations. Revenue was flat year-over-year on a core basis, which masked a 7% gain in biotech and a modest decline in life sciences, revealing the uneven recovery across business lines.
Looking ahead, sales guidance for the next quarter was ahead, while full year EPS guidance also beat Wall Street's expectations.
Overall, we think this was a solid quarter with some key areas of upside.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
After Monday’s broad-based sell-off — triggered by renewed pressure from President Donald Trump on Federal Reserve Chairman Jerome Powell, raising concerns over the integrity of central bank independence — Wall Street bounced back with strength on Tuesday, buoyed by upbeat signals from the corporate earnings sea
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Danaher posted Q1 revenue of $5.74 billion and EPS of $1.88, both above estimates, with bioprocessing and diagnostics driving better-than-expected results.
Diversified science and technology company Danaher (NYSE:DHR) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $5.74 billion. Guidance for next quarter’s revenue was better than expected at $5.92 billion at the midpoint, 1.9% above analysts’ estimates. Its non-GAAP profit of $1.88 per share was 14.4% above analysts’ consensus estimates.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (NASDAQ:ILMN) and the rest of the life sciences tools & services stocks fared in Q4.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
